May 12th 2024
Antimicrobial stewardship to reduce multidrug resistance and opportunistic Clostridioides difficile infection (CDI) could also guide shorter treatment.
Identifying High-Risk Recurrent Clostridioides Difficile Patients for Bezlotoxumab
April 18th 2022The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.
Read More
Fidaxomicin Versus Vancomycin for Clostridioides Difficile Treatment
April 15th 2022Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.
Read More
Ferring’s Microbiome Health Index Measures Gut Microbiota After Antibiotics
January 7th 2022Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection
Read More
Taking Care of Each Other: The Peggy Lillis Foundation for C Diff Education and Advocacy
December 14th 2021Christian Lillis, co-founder and executive director of the Peggy Lillis Foundation (PLF) for C diff Education & Advocacy, says that taking care of each other is often the best way to stop the spread of infectious diseases.
Watch